Lymphoma

Former U.S. goalkeeper opens up about a large B-cell lymphoma diagnosis and finally reaching remission after chimeric antigen receptor T cell therapy, urging patients to advocate and seek options.

Losing my cat after years alongside my cancer journey reminded me how much his presence eased stress, anxiety and treatment days.

An expert explains FDA-approved Lymphir for relapsed or refractory CTCL, noting 36% response rate, manageable side effects and fast relief from itching.

Kim Johnson shares her experience losing her sister to cancer, offering guidance for those grieving and for the people supporting them.

The FDA granted orphan drug designation to CTD402 for relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.

After five years in remission, a scan shows a small anomaly that might be recurrence, or it can show nothing, leaving a tense week before my oncologist visit.

Outpatient CD19 CAR-NK plus rituximab led to complete remissions up to 15 months in patients with Waldenström Non-Hodgkin lymphoma.

I have lived with both depression and cancer and know that illness, visible or not, ebbs and flows; canceled plans can reflect health limits, not rejection

Patients with relapsed/refractory diffuse large B-cell lymphoma who received Epkinly alone experienced an improvement in progression-free survival.

Now that I have been living with my chronic cancer for 16 and a half years, I’ve been reflecting on how my attitude has changed over time.

Dr. Ian Flinn explains how Lunsumio VELO works, offering an outpatient immunotherapy option with accelerated FDA approval.

Adding Monjuvi and Revlimid to standard chemotherapy helped patients with newly diagnosed lymphoma live longer without disease worsening.

I reflect on caregiving, loss and gratitude, honoring the people who supported me through my sister’s cancer and my first Thanksgiving without her.

Jace Yawnick explained why a support system is essential for patients with cancer.

It’s been two-and-a-half years since I “rang the bell” on the Oncology ward, signaling that I had ended my chemotherapy treatment.

The FDA granted review to a supplemental biologics license application for Opdivo plus chemo for previously untreated stage 3/4 classical Hodgkin lymphoma.

Real-world treatment with Yescarta demonstrated durable responses and manageable safety in patients with relapsed/refractory follicular lymphoma.

Dexamethasone before Yescarta reduced the severity of ICANS but did not change how often ICANS or CRS occurred in patients with LBCL.

Dr. Josh Brody discussed key clinical trial findings for patients with diffuse large B-cell lymphoma.

The phase 3 EPCORE FL-1 trial showed that adding Epkinly to Rituxan and Revlimid delivered superior PFS and response rates.

Among older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), Epkinly plus R-mini-CHOP appeared to be well tolerated and elicited responses.

Among patients with previously untreated diffuse large B-cell lymphoma, odronextamab has been associated with early efficacy.

I believe time to be a gift, and as such, my sister was gifted more than a decade despite a terminal illness, and I do have gratitude for that.

Facing my cancer diagnosis, I learned it’s okay not to be okay and found comfort in laughter, honesty, and the support of loved ones.

The FDA approved Breyanzi for adults with relapsed or refractory marginal zone lymphoma who received at least two prior lines of systemic therapy.